Acquiring Company
Nuformix PLC
Acquired Company
Biovara
United KingdomBiotechnologyHealth CareTherapeuticsPharmaceuticalBiotechnologyHealth CareMedicalTherapeuticsDescription
Nuformix has proposed to acquire Biovara in a share-for-share merger of equals. The deal would combine Biovara's LipAprep for lung cancer-related cough with Nuformix's NXP002 for idiopathic pulmonary fibrosis. The combined company would be a clinical-stage respiratory drug development business with two proprietary assets.
Other recent acquisitions in Therapeutics and Pharmaceutical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Acrivon Therapeutics Acquires Aqilion’s Drug Development Programs (November 6, 2026)
- Indivior Pharmaceuticals Completes Acquisition of Supernus Pharmaceuticals (November 2, 2026)
- Abeona Therapeutics to Acquire APT-1011 Assets from Ellodi Pharmaceuticals (November 9, 2026)
- Petauri acquires Franklin Pharmaceutical Consulting (October 8, 2026)
- Lifecore Biomedical Announces Merger with Lifecore Inc. (September 27, 2026)
- Vantive Enters Agreement to Divest Majority of Hemodialysis Assets to Rockwell Medical to Focus on Home Dialysis. (November 4, 2026)
Who to call at Nuformix PLC, and when
When Nuformix PLC changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Nuformix PLC raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Nuformix PLC, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Nuformix PLC. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Nuformix PLC makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Biovara?
Biovara was acquired by Nuformix PLC, based in United Kingdom. The deal was reported on November 11, 2026. Nuformix PLC is a pharmaceutical developer listed on the London Stock Exchange under the ticker NFX. It develops the NXP002 inhaled treatment for idiopathic pulmonary fibrosis and other lung scarring diseases. Nuformix PLC is privately held and operates in Biotechnology.
When did Nuformix PLC acquire Biovara?
Nuformix PLC's acquisition of Biovara was reported on November 11, 2026. Nuformix has proposed to acquire Biovara in a share-for-share merger of equals. The deal would combine Biovara's LipAprep for lung cancer-related cough with Nuformix's NXP002 for idiopathic pulmonary fibrosis. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Biovara do?
Biovara is a respiratory drug company developing LipAprep, a treatment for lung cancer-related cough that has completed a single-dose Phase 1 clinical study. It is privately held, operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.